Pharmaceutical Tools of the Trade

Pharmaceutical processors have begun to wield some new tools, nailing down new efficiencies and better drugs in the process.

Steven E. Kuehn, Editor in Chief
JanCover SN AIM8 Bosch

  Maslow wrote, “I suppose it is tempting, if the only tool you have is a hammer, to treat everything as if it were a nail.” For decades, Pharma’s been engineering its own “hammer,” creating development and production methodologies that tended to treat every potential drug candidate like the proverbial nail. To many, Pharma’s hammer became too heavy to wield, not only inefficient at driving Pharma’s traditional solid-dose nails but increasingly ineffective at addressing quality issues at the manufacturing level for biopharmaceuticals. Since FDA promulgated Pharmaceutical cGMPs for the 21st Century: A Risk-Based Approach, drug makers have invested in its…

Full Story

Don't Miss These Pharma Manufacturing Exclusives


On-demand, concise audio and powerpoint tutorials on the fundamental concepts of a range of pharmaceutical manufacturing, process development quality control and compliance topics.

Ask the Expert

We've assembled a roster of leading authorities in many fields to help you address technical issues. Pose a question or browse previous questions to find helpful answers.

Funny Pharm

Write a caption and win!

Feb15homepageBe sure to check out our newest cartoon created by award-winning artist Jerry King. He provides the artwork; you provide the funny caption!

Most Recent

  • Benchmarking BioPharma’s Amazing Ascent

    By Steven E. Kuehn, Editor in Chief

    Eric Langer and BioPlan Associates have been evaluating the biopharma and life sciences industry for nearly 25 years. This scrutiny became more formalized on the launch some 12 years ago of BioPlan’s familiar and perennial Annual Biopharmaceutical Manufacturing Report and Survey, its annual…

    Full Story
  • Can Current Investment in New Drugs Be Sustained?

    By Ernst Berndt, Professor, MIT Sloan School of Management

    When blockbuster drugs hit the market, they make big news and big profits. But for every blockbuster drug launched, there are an awful lot of disappointments.A good example is Vertex’s launch of the Hepatitis C drug Incivek. It was extremely successful in its first year on the market and heralded…

    Full Story
  • Process Cooling as Part of a Sustainable Strategy

    By Al Fosco, Frigel North America

    While the pharmaceutical industry continues on its road to recovery, sustainability will remain a priority for pharmaceutical manufacturers as they strive for profitable growth. One way many can make significant headway toward true sustainability — and improve the bottom line — is through the…

    Full Story
  • Managing Pharmaceutical Supply Chain Risks

    By Daniel S. Brettler, Managing Director, SVP, Life Science and Technology Practice Leader for Conner Strong & Buckelew

    Pharmaceutical manufacturers’ supply chains have become increasingly complex in a globalized economy. There may have been a simpler time when insurance was viewed as a commodity, but today’s policies should be intricately tailored to a company’s specific operations. In other words, a…

    Full Story
  • Bioreactor Preferences from an Outsourcing Perspective – Part I

    By Kshitij (TJ) Ladage, market research manager, That’s Nice

      Considering the capacious amount of time and resources an organization invests in bringing a biologic to market, bioreactor selection is one of the crucial manufacturing decisions for an organization. Unlike small molecule, the cost of production plays a vital role in the pricing of biologics.

    Full Story
  • Seeing Snowflakes in a Snow Storm

    By Steven E. Kuehn

    Were you planning to attend the 29th International Forum for Process Analytical Chemistry (IFPAC) annual meeting in Arlington, Virginia, but something white and fluffy got in the way? You certainly weren’t alone, but darn it if you didn’t miss a good meeting this year. Many would agree, I…

    Full Story

Latest Products